fbpx
01 / 05
The Myth of the “Autism Epidemic”

Blog Post | Health & Demographics

The Myth of the “Autism Epidemic”

Most new cases reflect mild or no significant impairment. Moderate and severe cases have declined.

Summary: The perceived “autism epidemic” is largely driven by broadened diagnostic criteria and increased identification of mild, non-impairing cases rather than a true increase in severe autism. Cultural and institutional factors—like overdiagnosis and shifting norms in child psychiatry—play a significant role. Public health efforts are being misdirected by alarmist narratives and should instead focus on genuine health crises and more consistent, clinically meaningful diagnostic standards.


For years, public health debate has often fixated on a supposed rise in the prevalence of autism. Various culprits have been named, including the well-investigated but unsubstantiated claim that vaccines cause autism. More recently, additional risk factors have been proposed — many by Health Secretary Robert F. Kennedy Jr. — including maternal Tylenol use, food dyes and additives, chemical manufacturing agents and other possible stressors affecting perinatal development. Concerns about autism have been spotlighted within the larger Make America Healthy Again movement, motivated by a well-founded alarm over the nation’s devastatingly high burden of chronic disease and psychiatric illness. But there is a bigger problem with the autism epidemic: It doesn’t exist.

Autism diagnoses have indeed risen dramatically in recent decades. The most recently released Centers for Disease Control and Prevention report on autism, which was published in April last year, revealed a nearly five-fold increase in the prevalence of autism between 2000 and 2022, from 67 to 322 cases per 10,000 children. However, diagnostic criteria can change even when the underlying health phenomenon remains unchanged. A large-scale study published in December, drawing on CDC data from 24,669 8-year-olds across the country, suggests that the dramatic rise in autism diagnoses may be entirely driven by children with mild symptoms and no significant functional impairment. Between 2000 and 2016, there was a 464 percent increase in diagnoses among children with no significant functional impairment whatsoever. In fact, during the same time period, there was a 20 percent decrease in the prevalence of moderate or severe autism, from 15 to 12 cases per 10,000 children.

There is often a lag of several years before such epidemiological datasets are released, and years more for researchers to perform statistical analyses, publish the findings and enter public policy discussions. We do not yet have data more recent than 2016 breaking down symptoms by severity level while controlling for other psychological factors such as intellectual disability. However, given the trends observed between 2000 and 2016, it is highly unlikely that the additional 74 percent increase in autism diagnoses between 2016 and 2022 reflects a sudden surge in severe, functionally impairing autism. Rather, it is more likely a continuation of the same problem of overrepresentation among children with mild symptoms and no significant functional impairment.

Despite that, some advocates support the narrative that autism is on the rise, because an ever-expanding “spectrum” that produces more diagnoses draws more attention and research funding — even if children’s underlying psychology remains unchanged.

Some of the CDC’s data documenting the supposed rise in the characteristics of autism, meanwhile, comes not from gold-standard in-person psychiatric assessments but from parent-reported surveys such as the Social Responsiveness Scale. The SRS includes statements such as “Would rather be alone than with others,” “Has difficulty making friends,” and “Is regarded by other children as odd or weird,” which parents rate from “Not true” to “Almost always true.” In my own doctoral research on adolescent mental health, I included the SRS to account for the extent to which other psychological outcomes were explained by social difficulties. However, I was always careful to use hedging language — these are behavioral traits known to be associated with autism, not diagnostic markers. Unfortunately, many studies use high scores on the SRS as a substitute for clinical assessment of autism — accounting, for example, for at least 12 percent of “suspected cases” in the 2022 CDC data.

We should be concerned about the rising number of quirky children “on the spectrum,” but not because they are being exposed to neurotoxins that older generations were insulated from, nor because a growing number of children face clinicallysignificant social impairment. Rather, as Abigail Shrier argues in her 2024 book “Bad Therapy,” the more pressing concern may be a cultural and institutional drift toward overdiagnosis across child psychiatry. Like the rise in attention-deficit/hyperactivity disorder, anxiety and depression diagnoses among young people, the surge in autism labels may reflect shifting norms, looser diagnostic criteria and excess therapeutic attention directed toward ordinary struggles. If autism were truly increasing because of a new environmental insult, we would expect to see increases across all levels of severity. But that is not the case.

This reality should fundamentally reshape our national conversation. Policymakers and public health officials have rallied around dramatic claims fueled more by fear than by evidence. Yes, America faces a real crisis of chronic disease — including obesity, metabolic dysfunction and autoimmune disorders — which plausibly could be impacted by environmental toxins. Yes, many children face real mental health challenges that warrant increased attention and psychiatric support. But neither of these narratives survives scientific scrutiny when applied to the rise in autism diagnoses.

When public discourse starts from an alarming headline — “Autism rates have quadrupled” — even careful scientists can be pressured into chasing explanations for a biological phenomenon that doesn’t exist. The result is a misallocation of scientific effort and a blurring of the real signals of environmental harm. In many cases, the kid labeled “on the spectrum” is the same train‑obsessed third‑grader your grandfather knew, only now he’s been assigned a diagnosis. Let’s instead direct public health toward real, ongoing health crises and insist on psychiatric criteria that are consistent, unexaggerated and clinically meaningful.

A version of this article was published at the Washington Post on 2/10/2026.

Science | Health Systems

AI Is Starting to Beat Doctors at Making Correct Diagnoses

“If you walk into an emergency room (ER) in 10 years, you’ll encounter a new type of caregiver: an artificial intelligence (AI) system designed to get you a diagnosis faster and help your care team make more informed decisions. While you sit in the waiting room, you’ll be hooked up to a blood pressure cuff that’s constantly and autonomously monitored. All the while, an AI agent will be listening in while you and your doctor talk about your symptoms, ready to flag any mistakes your physician makes or suggest next steps.

This vision of AI-assisted emergency health care may soon be reality. In a new study, researchers show that a type of AI known as a large language model (LLM) often outperformed physicians at diagnosing complex and potentially life-threatening conditions, including decreased blood flow to the heart, even in the fast-moving stages of real ER care when information is limited, they report today in Science. In early ER cases, the model identified the correct or a very close diagnosis in about 67% of cases, compared with roughly 50% to 55% for physicians. And the technology is only getting better.”

From Science.

The Guardian | Health Systems

First Malaria Drug for Babies Is Approved in Major Milestone

“The first malaria treatment for babies has been approved by the World Health Organization, opening the door to widespread use around the globe.

In parts of Africa, up to 18% of children under six months will be infected with malaria, but there has historically been no safe treatment for the smallest of them. There were 610,000 deaths from malaria in 2024, about three quarters of which were under-fives in Africa…

Medical leaders hope that Coartem Baby, which can be used to treat infants as small as 2kg (4.4lb), will fill the treatment gap. The drug comes as sweet cherry-flavoured tablets that can be dissolved into liquids, including breast milk…

Coartem Baby now has WHO prequalification, which indicates it meets international standards of quality, safety and efficacy, and will enable public-sector procurement for many countries with high rates of malaria, particularly in sub-Saharan Africa.”

From The Guardian.

Reuters | Health Systems

J&J Sees AI Halving the Time to Generate Drug Development Leads

“Johnson & Johnson is using artificial intelligence to slash by half the time it ‌takes to generate new leads for developing drugs, the company’s chief information officer said on Monday.

Discovering new products outright and bringing them to market using AI is not yet possible, but J&J is using the new technology to screen the “potential universe” for promising chemical compounds or ​biologics, CIO Jim Swanson said at the Reuters Momentum AI event in New York…

J&J is also using AI to streamline preparation of documents for regulators. The traditional process for a clinical trial report can take 700 to 900 hours, the CIO ​said.
That time has gone from ‘700 ​hours to about 15 ⁠minutes,’ Swanson said.”

From Reuters.

Financial Times | Health Systems

Indian Weight-Loss Market Booms as Drugmakers Pile In

“After last month’s expiry of Indian exclusivity on the patent for semaglutide, the active ingredient in Ozempic and Wegovy, she expects even greater demand as the world’s largest producer of generic medicines also becomes a big consumer of weight-loss drugs…

Analysts at Nomura estimated Indian drugmakers could charge Rs3,500-Rs8,000 ($37-$85) a month for disposable pen injections, far lower than the Rs11,000-Rs16,000 for western branded versions.”

From Financial Times.